| pubmed-article:6530609 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C0030567 | lld:lifeskim |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C0927232 | lld:lifeskim |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C0457454 | lld:lifeskim |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C1154437 | lld:lifeskim |
| pubmed-article:6530609 | lifeskim:mentions | umls-concept:C1444662 | lld:lifeskim |
| pubmed-article:6530609 | pubmed:issue | 2-3 | lld:pubmed |
| pubmed-article:6530609 | pubmed:dateCreated | 1985-4-26 | lld:pubmed |
| pubmed-article:6530609 | pubmed:abstractText | The dopamine turnover rate in the central nervous system (CNS) of parkinsonian patients was studied by means of the intravenous probenecid test during drug holiday (DH) and alternate day L-dopa therapy (ADDT). After L-dopa therapy was stopped, the dopamine turnover rate decreased more rapidly in patients with the marked wearing-off phenomenon than that in patients without fluctuation of symptoms. The lumbar CSF concentrations of L-dopa and 3-O-methyldopa of patients with and without wearing-off phenomenon were similar during L-dopa therapy. DH improved the effect of L-dopa on parkinsonian symptoms; it did not affect, however, the metabolism of exogenous L-dopa. The dopamine turnover rate in the CNS before L-dopa therapy or on on-days did not differ between patients tolerating and those not tolerating ADDT. However, it was significantly lower on off-days in patients not tolerating ADDT than in those tolerating ADDT. The relationship between dopamine storage in the CNS and the response to L-dopa therapy is discussed. | lld:pubmed |
| pubmed-article:6530609 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6530609 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6530609 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6530609 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6530609 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6530609 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6530609 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6530609 | pubmed:issn | 0022-510X | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:TaruiSS | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:TakahashiMM | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:WadaKK | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:NakamuraYY | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:NishikawaYY | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:YorifujiSS | lld:pubmed |
| pubmed-article:6530609 | pubmed:author | pubmed-author:OgasaharaSS | lld:pubmed |
| pubmed-article:6530609 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6530609 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:6530609 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6530609 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6530609 | pubmed:pagination | 151-63 | lld:pubmed |
| pubmed-article:6530609 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:meshHeading | pubmed-meshheading:6530609-... | lld:pubmed |
| pubmed-article:6530609 | pubmed:articleTitle | Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease. | lld:pubmed |
| pubmed-article:6530609 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6530609 | lld:pubmed |
